Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46. https://doi.org/10.1158/2159-8290.CD-21-1059.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24. https://doi.org/10.1056/NEJMoa065044.

Article  CAS  PubMed  Google Scholar 

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8. https://doi.org/10.1200/JCO.2009.23.9764.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. https://doi.org/10.1056/NEJMoa0708857.

Article  CAS  PubMed  Google Scholar 

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12. https://doi.org/10.1016/S0140-6736(12)61900-X.

Article  CAS  PubMed  Google Scholar 

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96. https://doi.org/10.1056/NEJMoa1103799.

Article  CAS  PubMed  Google Scholar 

US FDA. Sorafenib NDA approval letter; 2005. Available at: http://www.Accessdata.Fda.Gov/Drugsatfda_docs/Appletter/2005/021923ltr.Pdf.

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12:27. https://doi.org/10.1186/s13045-019-0718-5.

Article  PubMed  PubMed Central  Google Scholar 

Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. Eur J Cancer Suppl. 2013;11:172–91. https://doi.org/10.1016/j.ejcsup.2013.07.016.

Article  Google Scholar 

Sehdev S. Sunitinib toxicity management: a practical approach. Can Urol Assoc J. 2016;10:S248–51. https://doi.org/10.5489/cuaj.4296.

Article  PubMed  PubMed Central  Google Scholar 

Ko Y, Tan S-LD, Chan A, Wong Y-P, Yong W-P, Ng RC-H, et al. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther. 2012;34:1696–704. https://doi.org/10.1016/j.clinthera.2012.06.025.

Article  PubMed  Google Scholar 

Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, et al. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation. 2022;145:e811–38. https://doi.org/10.1161/CIR.0000000000001056.

Article  PubMed  Google Scholar 

Bhatt VR. Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities. Future Oncol. 2019;15:2557–60. https://doi.org/10.2217/fon-2019-0159.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34:2366–71. https://doi.org/10.1200/JCO.2015.65.4327.

Article  PubMed  PubMed Central  Google Scholar 

Bertholee D, Maring JG, van Kuilenburg ABP. Genotypes affecting the pharmacokinetics of anticancer drugs. Clin Pharmacokinet. 2017;56:317–37. https://doi.org/10.1007/s40262-016-0450-z.

Article  CAS  PubMed  Google Scholar 

Ling WHY, Lee SC. Inter-ethnic differences-How important is it in cancer treatment? Ann Acad Med Singap. 2011;40:356–61.

Article  PubMed  Google Scholar 

Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30:1371–7. https://doi.org/10.1200/JCO.2011.36.4133.

Article  CAS  PubMed  Google Scholar 

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32:1412–8. https://doi.org/10.1200/JCO.2013.50.8267.

Article  CAS  PubMed  Google Scholar 

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6: e1000100. https://doi.org/10.1371/journal.pmed.1000100.

Article  PubMed  PubMed Central  Google Scholar 

Wells G, Shea B, O’Connell D, Peterson JE, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 3rd Symposium on Systematic Reviews: Beyond the Basics; 3–5 July 2000: Oxford.

Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, et al. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. J Hematol Oncol. 2018;11:69. https://doi.org/10.1186/s13045-018-0617-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage. 2004;27:14–23. https://doi.org/10.1016/j.jpainsymman.2003.06.003.

Article  PubMed  PubMed Central  Google Scholar 

Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788–95. https://doi.org/10.1038/sj.bjc.6603813.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mourad J-J, Levy BI. Mechanisms of antiangiogenic-induced arterial hypertension. Curr Hypertens Rep. 2011;13:289–93. https://doi.org/10.1007/s11906-011-0206-y.

Article  CAS  PubMed  Google Scholar 

Kim K-A, Joo H-J, Park J-Y. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations. J Clin Pharm Ther. 2010;35:705–12. https://doi.org/10.1111/j.1365-2710.2009.01127.x.

Article  PubMed  Google Scholar 

Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, et al. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013;72:825–35. https://doi.org/10.1007/s00280-013-2258-y.

Article  CAS  PubMed  Google Scholar 

Huang L, Hu C, Di Benedetto M, Varin R, Liu J, Wang L, et al. Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib. Onco Targets Ther. 2014;7:2249–55. https://doi.org/10.2147/OTT.S67251.

Article  PubMed  PubMed Central  Google Scholar 

Pedersen JK, Engholm G, Skytthe A, Christensen K. Cancer and aging: epidemiology and methodological challenges. Acta Oncol. 2016;55:7–12. https://doi.org/10.3109/0284186X.2015.1114670.

Article  PubMed  PubMed Central  Google Scholar 

Centers for Disease Control and Prevention. United States Cancer Statistics: Highlights from 2019 Incidence. USCS Data Brief, no. 29. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2022.

Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383–9. https://doi.org/10.1200/JCO.2003.08.010.

Article  PubMed